Nonalcoholic fatty liver. Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention 1: Control group: daily 2 g dextrin as 4 capsules of 500 mg. Intervention 2: Intervention group: daily 2 g sumac as 4 capsules of 500 mg.
Treatment - Drugs
Control group: daily 2 g dextrin as 4 capsules of 500 mg
Intervention group: daily 2 g sumac as 4 capsules of 500 mg
Sponsors
Vice Chancellor for Research of Iran university Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: The criteria for inclusion: Age 20-60 years of both sexes, fatty liver disease be approved by physician gastroenterologist based on the following criteria: (ultrasound, volume Alastvmtry in fiberscan and> 4 kPa (kpa) or are in the process of steatosis S1 and Alanine transferase more than 5.1 times the upper limit of normal (women and men), Body Mass Index (BMI)25-29/9), a interested in participating the plan and received written informed consent, lack of participation in other projects. Exclusion criteria:The patient's unwillingness to continue cooperation with the Started taking the drug during the intervening period, Change the type or dose, Change in diet or physical activity program, Weight loss more than 10% of initial body weight during the intervention , Any use of antioxidant supplements, vitamins or minerals , Less than 80% supplements delivered to the patient at baseline, Start smoking during the intervening period, Become pregnant during treatment, Surgery and psychosomatic problems during the intervention, The use of all anti-NASH (vitamin E, thiazolidinedione, UDCA gemfibrozil,), Developing other liver diseases, kidney, kidney stones, cancer, hypothyroidism or hyperthyroidism, allergies, trauma during the intervention
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Alanine aminotransferase. Timepoint: Before the start of treatment and 12 weeks after intervention. Method of measurement: Spectrophotometry.;Aspartate aminotransferase. Timepoint: Before the start of treatment and 12 weeks after intervention. Method of measurement: Spectrophotometry.;Hepatic steatosis. Timepoint: Before the start of treatment and 12 weeks after intervention. Method of measurement: Using the scanning fiber 502. | — |
Secondary
| Measure | Time frame |
|---|---|
| Total cholestrol. Timepoint: Before the start of treatment and 12 weeks after intervention. Method of measurement: Spectrophotometry.;Triglycerides. Timepoint: Before the start of treatment and 12 weeks after intervention. Method of measurement: Spectrophotometry.;Low density lipoprotein. Timepoint: Before the start of treatment and 12 weeks after intervention. Method of measurement: Spectrophotometry.;High density lipoprotein. Timepoint: Before the start of treatment and 12 weeks after intervention. Method of measurement: Spectrophotometry.;Leptin. Timepoint: Before the start of treatment and 12 weeks after intervention. Method of measurement: Elisa. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Farzad Shidfar
Iran University Medical Sciences
Outcome results
None listed